A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Urinary incontinences is a highly prevalent and distressing condition which has a significant impact on health related quality of life in millions of women worldwide. Of all women with incontinence, 90% will have overactive bladder symptoms (OAB), and 50% will have detrusor overactivity (DO) on cystometry. The overactive bladder syndrome is defined by the International Continence society as "Urinary urgency, with or without urge incontinence, usually with frequency and nocturia if there is a no infection or proven pathology" (Abrams et al 2002)

Initial management of OAB and DO consists of conservative measures such as altering fluid intake, bladder retraining and drug therapy. The next step consists of interventions such as cystoscopy and urethral dilatation, on the basis that it will allow intrinsic bladder problems such as interstitial cystitis to excluded, excluded, and may confer a symptomatic benefit.

The original study showed no benefit of urethral dilatation versus no dilatation at 6 months follow up (Duckett 2007). The investigators do not know the natural history of patients with voiding dysfunction. Therefore reviewing their symptoms will give a better idea of what happens to these patients symptoms over time.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cystoscopy and Cystodistension; Therapeutic and Aetiological Aspect in Overactive Bladder

NCT01971437

Urinary Incontinence, Urge

COMPLETED NA

Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding

NCT00839969

Overactive Bladder Syndrome Voiding Dysfunction

UNKNOWN NA

Interstitial Cystitis (IC)-Like Findings With Hydrodistension

NCT02547298

Interstitial Cystitis

TERMINATED

Evaluation of Fluorescein Use During Cystoscopy

NCT02703558

Intraoperative Cystoscopy

WITHDRAWN NA

A Study of the Effect of Antibiotics on the Microbiology of the Bladder in Patients With Overactive Bladder

NCT02536872

Urogynaecology

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Urinary incontinences is a highly prevalent and distressing condition which has a significant impact on health related quality of life in millions of women worldwide. Of all women with incontinence, 90% will have overactive bladder symptoms (OAB), and 50% will have detrusor overactivity (DO) on cystometry. The overactive bladder syndrome is defined by the International Continence society as "Urinary urgency, with or without urge incontinence, usually with frequency and nocturia if there is a no infection or proven pathology" (Abrams et al 2002)

Initial management of OAB and DO consists of conservative measures such as altering fluid intake, bladder retraining and drug therapy. The next step consists of interventions such as cystoscopy and urethral dilatation, on the basis that it will allow intrinsic bladder problems such as interstitial cystitis to excluded, excluded, and may confer a symptomatic benefit.

Cystoscopy and urethral dilatation have long been advocated as empirical treatments for women with lower urinary tract symptoms (LUTS). A review of the literature reveals a marked lack of evidence regarding the survey of practice amongst UK urologists found that 61% had performed urethral dilatation 7 or more times during the year in which the survey was conducted, although 55% believed that less than half of the patients experience long term improvement (Masarani and Willis, 2006)

The original study showed no benefit of urethral dilatation versus no dilatation at 6 months follow up (Duckett 2007). The investigators do not know the natural history of patients with voiding dysfunction. Therefore reviewing their symptoms will give a better idea of what happens to these patients symptoms over time. The aim of the study is to identify any long term benefit from urethral dilatation over cystoscopy alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder Voiding Dysfunction Urinary Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cystoscopy Alone

Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.

Cystoscopy only

Intervention Type PROCEDURE

Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction

Cystoscopy & Urethral Dilatation

Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.

Cystoscopy and Urethral dilatation

Intervention Type PROCEDURE

Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cystoscopy only

Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction

Intervention Type PROCEDURE

Cystoscopy and Urethral dilatation

Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Significant Overactive Bladder Symptoms

* Based on scoring 1 or 2 on the Urgency Perception Scale
* On the symptoms domain of the KHQ
* More than 8 voids per day on frequency volume chart +/- 2 or more episodes of nocturia
2. Pressure flow studies demonstrate a maximum flow rate of less than 15ml on a minimum voided volume of 200ml with a high or normal detrusor pressure at maximum flow or post-void residual of 200ml or over
3. Patients must be able to give informed consent for the study.

Exclusion Criteria

1. Presence of concurrent urodynamic stress incontinence.
2. Patients with bladder pathology or haematuria of unknown origin.
3. Patients with neurological disorders (as these may affect voiding).
4. Symptomatic pelvic organ prolapse requiring intervention
5. Patients with bladder pathology (including urinary tract infection) or haematuria of unknown origin

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No